 Cell Therapies |
||
| Cell Therapies delivers flexible solutions across the full spectrum of clinical trials involving cell and tissue manipulation | |||||||
a focused unit to execute all contract engagements
Cell Therapies has been set up to manage the commercial interface to the CPC.
Cell Therapies Pty Ltd. provides clients and collaborators with a focused business unit that is able to negotiate and execute all business aspects of contract engagements. We are able to provide access to the hospital’s wider expertise in advanced imaging, clinical trial design and approval, recruitment of principal investigators and patients, licensed manufacture, audit compliance, clinical interpretation, and reporting. We build on our experience in protocol development and SOP preparation, while matching research imperatives to licensed production restraints.
About Cell Therapies Pty Ltd | 
- Regulation of Cell Therapies DOC.PDF 82Kb Dominic Wall and Miles PrinceRegulation of Cellular Therapies: the Australian Perspective
- Cell processing DOC.PDF 472KbH. Miles Prince, Dominic P. Wall, Kerrie H. Stokes, Ray Wood, Scott R. Burger, Patrick Coghlan and Neil BoyceCell processing for clinical trials and commercial manufacture
- I.S.C.T. Poster DOC.PDF 2.2MBC.M Wall, H.M Prince, L.Mileshkin, M.Thompson, J. Coverdale, R.J Hicks; Centre for Blood Cell Therapies, Peter MacCallum Centre, MelbourneI.S.C.T. Poster of Sequential tomographic tracking and localisation
- IDM Poster ASCO DOC.PDF 203KbI. Gorin, M. Prince, J. Grob, M-T. Leccia, T. Lesimple, E. Ferriès, N.Bercovici, E.Tartour, R.Taylor, C. Robert Hôpital Tarnier-Cochin Paris France; Peter MacCallum Cancer Centre, East Melbourne Australia; Hôpital Ste Marguerite Marseille France; Hôpital Michallon Grenoble France; Centre Eugène Marquis Rennes France; IDM S.A. Paris France; Hôpital Européen Georges Pompidou Paris France; Institut Gustave Roussy Villejuif FranceA phase I/II study of a multivalent dendritic cell vaccine in patients with metastatic melanoma
- IDM Press Release ASCO DOC.PDF 54KbIDM will present phase III trial results for it's melanoma cancer vaccine Uvidem® at ASCO (Orlando) on May 15 2005IDM Press Release ASCO
- Cancer Vaccines/Adjuvants/Delivery - Lisbon DOC.PDF 77KbFor Cancer Vaccines/Adjuvants/Delivery for the Next Decade 5-7 Septembre 2005, Lisbon PortugalCancer Vaccines/Adjuvants/Delivery - Lisbon
- In Vivo Cell Tracking DOC.PPT 858KbIn Vivo DC TrackingCell Tracking Powerpoint Presentation
- Transplantation of Autologous Peripheral Blood Stem Cells DOC.PDF 647 kbA. Yallourdis, P. Gambell, D. Wall, K. Stokes, H. M. PrinceView Poster
- Tracking Dendritic Cells DOCPDF 211KbMiles Prince1*, Dominic M Wall1*, David Ritchie1*,Dirk Honemann1*, Simon Harrison1*, Hang Quach 1*, Mick Thompson2*, Rodney Hick2*,Eddie Lau2*, Jill Davison1,Maureen Loudovaris1*, Jude Moloney1*, Bruce Loveland3, Jacques Bartholeyns4*, Andrew Katsifis5*, Linda Mileshkin*Tracking Dendritic Cells
- Technological Trajectories and Stem Cell DOC.PDF 805KbSarah Haecker, Ray WoodTechnological Trajectories and Stem Cell "Dominant Design"
- Prediction of CD34+ PBSC Collection DOC.pdf 300 KbP. Gambell, A. Yallouridis1 D. Wall, K. Stokes, A. Milner, M Dickinson, H. M. PrincePrediction of CD34+ PBSC Collection
- Analysis and Characterization of Antitumor T-cell Response DOC459KBNadege Bercovici, Nacilla Haicheur, Severine Massicard, Frederique Vernel-Pauillac, Olivier Adotevi, Didier Landais, Isabelle Gorin,J Caroline Robert, H. Miles Prince, Jean-Jacques Grob, Marie Thérése Leccia, Thierry Lesimple, John Wijdenes, Jacques Bartholeyns, Wolf H. Fridman, Margarita Salcedo, Estelle Ferries, and Eric TartourwzAnalysis and Characterization of Antitumor T-cell Response
- Opening the Gates to Autologous Cellular Therapies DOC.PDF 67KbBy Edward Scott MD, medical director and CEO of the Mid-South Regional Blood Center (Lifeblood) and Lifeblood Biological Services LLC in Memphis, TennesseeAutologous Cellular Therapies
- Clinical and Commercial Solutions DOC.PDF 1.04MBCell Therapies Pty Ltd brings world-best research and science together with astute commercial operationsClinical and Commercial Solutions
- Update on Peter Mac and CT Research Activities DOC.PDF 445KbOne of the most exciting aspects of being a researcher at Peter Mac is the opportunity to take discoveries from the lab to the clinic.Effective collaboration between laboratory and clinical researchers is vital for improving the outcomes of patients with cancer
- First Culture Expanded Adult Stem Cell Therapy DOC.PDF 50KbA. Evans, N. McCarthy, D. Wall, K. Stokes, M. Bleasdale, D. Ritchie, H.M. Prince, K. Kelly and S. ItescuObtaining Manufacturing Approval for the First Culture Expanded Adult Stem Cell Therapy under an Evolving Regulatory Framework: Challenges and Opportunities
- Newly Developed Nanoparticles for Cell Tracking DOC.PDF 1.42MBGiovanni Mandarano, Jyoti Arora, Dominic Wall, Simon Harrison, Noelene Bergen, Dodie Pouniotis and Peter EuNewly developed nanoparticles for cell tracking using magnetic resonance imaging
- Commercializing Therapies Alongside an Academic Institution DOC.PDF 840KbRay Wood Managing Director Cell Therapies Pty LtdCommercializing Cell Based Therapies within or alongside an Academic Institution
- Regulation of Cellular Therapies: the Australian Perspective PDFA recent update of the manufacture of Cell-based products in Australia as they pertain to governances and scrutiny.
- Clean RoomsFloor layout and description of the lab premises utilized by Cell Therapies Pty Ltd.
- Contact PageTelephone, email and addresses of the principals and affiliates of Cell Therapies Pty Ltd.
- Clinical Trials PortfolioA list of clinical trials current and recent
- Fully Licensed FacilityPeter Mac's CBCT was the first cGMP and Therapeutic Goods Administration-accredited laboratory in Australia. CBCT has worked collaboratively with the TGA and others including the Gene Manipulation Advisory Committee and the Gene Therapy Research Advisory Panel of the National Health and Medical Research Council.
- Raymond Wood FIE Australia, FAICDRay Wood Managing Director is a graduate of the NSW Institute of Technology and Macquarie University’s Advanced Management Program
- Staff of Cell TherapiesCell Therapies, through the Centre for Blood Cell Therapy combines leading scientists and researchers.
- Special Laboratory FeaturesSpecial environmental control systems and features of the Centre for Blood Cell Therapies clinical and research areas
- Quality Assurance SystemsQuality assurance in commercial solutions for the manipulation of human tissue at the Centre for Blood Cell Therapies
- Associate Professor H. Miles PrinceAssoc Professor Miles Prince is the Head of the Haematology Unit at Peter MacCallum Cancer Centre, Melbourne, Australia and Director of the Blood and Marrow Transplant Service and the Edith Margaret Collie Centre for Blood Cell Therapies.
- Dr Dominic Wall BSc (Hons) PhDDr Dominic Wall is the Production Manager for the Centre for Blood Cell Therapies (CBCT) and is the production nominee cited for the purposes of licensing by the Therapeutics Goods Administration.
- Cell Therapies Pty LtdCT is in the business of planning and conducting clinical trials
- About Cell TherapiesCell Therapies Pty Ltd is in the business of planning and conducting clinical trials that involve the collection, manipulation and storage of blood cells and human tissue
- Who Are Cell TherapiesCell Therapies, through the Centre for Blood Cell Therapies, provides clients and collaborators with a focused business unit, able to negotiate and execute all commercial aspects of for-fees engagements
- Why Cell Therapies?Cell Therapies Pty Ltd holds an intimate knowledge of regional and international regulatory requirements for CT, a vital resource for companies entering into commercialization.
In association with
Cell Therapies Pty Ltd ABN 100 285 916